In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Eliquis (apixaban) was approved by the FDA in 2012. Pfizer and Bristol-Myers Squibb are the two drug companies responsible for Eliquis.
Eliquis does not have an antidote for a patient experiencing a trauma-induced bleeding event or needing emergency surgery.
Our law firm is handling Eliquis cases which involve people who had excessive bleeding, bled to death, or experienced other serious side effects of Eliquis.
These medical conditions may have been caused by the use of Eliquis:
• Serious Bleeding Events
• Irreversible Fatal Bleeding Events
• Trauma-induced Atypical Bleeding Incidents
• Gastrointestinal (GI) Bleeds
• Rectal Bleeding
• Brain Hemorrhage
• Intracranial Hemorrhage
• Hemorrhagic Stroke
• Cardiac Bleeds
• Heart Attacks
• Myocardial Infarction (MI)
• Acute Coronary Syndrome (ACS)
While an Eliquis antidote, or reversal agent, will someday be available to help patients suffering an acute bleed, unfortunately it is too late for some people who suffered serious bleeding events or bled to death, already.
Here are some of the personal injury and wrongful death cases involving Eliquis-related bleeding events that we are investigating:
Eliquis – Irreversible Fatal Bleeding during Surgery – 73 yr old woman
Eliquis – Fatal Cardiac Arrest caused by Cardiac Tamponade – 67 yr old man
Eliquis – Serious Bleeding Episode – 59 yr old man
Eliquis – Hemorrhagic Stroke (CVA) – 66 yr old woman
Eliquis – Brain Hemorrhage (8 wks. hospitalization) – 87 yr old man
Eliquis – Hemorrhagic Stroke / Brain Bleed – 76 yr old woman
Eliquis – Gastrointenstinal Bleeding; “Coagulopathy due to Eliquis” (Death Certificate)
Eliquis – Serious Bleeding Event – 70 yr old man
Eliquis – Sudden Severe Brain Bleed leading to Death – 82 yr old man
Eliquis – Trauma-induced Atypical Bleeding – 76 yr old woman
We encourage you to submit a Drug Injury Law Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
In the federal court system, there are now more than 50 Eliquis lawsuits filed, and more of these drug injury and death cases are expected. Given this situation, in early February 2017 the United States Judicial Panel on Multidistrict Litigation (JPML) established this consolidation of all federal court Eliquis cases, IN RE: ELIQUIS (APIXABAN) PRODUCTS LIABILITY LITIGATION — MDL No. 2754.
From the February 7, 2017 JPML Order establishing this Eliquis federal court MDL we get this information about the litigation:
[W]e find that these actions involve common questions of fact, and that centralization will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation. All the actions share common factual questions arising out of allegations that plaintiffs suffered severe bleeding and related injuries as a result of taking Eliquis (apixaban), that defendants did not conduct sufficient testing of the drug, and that defendants’ warnings and instructions as to the alleged risks, including the unavailability of a reversal agent to counteract bleeding, were inadequate. Issues concerning the design, testing, manufacture, regulatory approval, labeling, and marketing of Eliquis thus are common to all actions….
We conclude that the Southern District of New York is an appropriate transferee district for this litigation. Common defendants BMS and Pfizer both have their corporate headquarters within the district, and therefore relevant documents and witnesses are likely to be located there. Sixteen actions on the motion and three potential tag-along actions are pending there.
In addition to the federal court Eliquis cases, there are a significant number of Eliquis lawsuits filed in the California state court system. As a result, a petition to coordinate those California Eliquis cases was submitted to the Chair of the Judicial Council seeking to establish a consolidation, there, which would be similar to the federal court Eliquis MDL.
In California, if that petition to coordinate the Eliquis lawsuits — which was submitted to the Chair of the Judicial Council (the Chief Justice) and then assigned to a motion judge for determination — is granted, its result would be called the California Eliquis JCCP (Judicial Council Coordination Proceedings).
It is currently expected that the determination about the creation of this California Eliquis JCCP will be made in the next couple of months.
Earlier articles by attorney Tom Lamb on the Side Effects Blog:
- Defendants BMS And Pfizer Ask For Eliquis Federal Court Consolidation
- Is Eliquis A Safe Alternative To Warfarin For Patients On Dialysis?
- No Clinical Trials Comparing The Safety Of Eliquis To Xarelto Done Yet
- Eliquis Lawsuits Being Filed Across The Country In Increasing Numbers
- Antidote Drug For Xarelto / Savaysa / Eliquis Is Denied FDA Approval
- Possible Blood Level Testing For Eliquis / Xarelto / Pradaxa / Savaysa
- Eliquis, Savaysa, And Xarelto Worry Doctors Because No Antidote, Still
- Eliquis Might Be Safer Than Xarelto, But Neither Has Approved Antidote
- Xarelto / Savaysa / Pradaxa / Eliquis: Effect Of Platelet Inhibitors
- No Antidotes For Eliquis, Savaysa, And Xarelto To Stop Acute Bleeding
- Eliquis Antidote Will Come Too Late For People Who Suffered Serious Bleeding Events, Some Which Caused The Deaths Of Patients
- Because No Antidote For Eliquis Is Available To Reverse The Effects Of Anticoagulation, There Have Been Irreversible Life-Threatening And Fatal Bleeding Events
All content by attorney Tom Lamb